Appraisal of immune response in lymphoproliferative syndromes: A systematic review

被引:12
作者
Alvaro, Tomas [1 ]
Lejeune, Marylene [1 ]
Escriva, Patricia [1 ]
Pons, Lluis E. [1 ]
Bosch, Ramon [1 ]
Jaen, Joaquin [1 ]
Lopez, Carlos [1 ]
Salvado, Maria-Teresa [1 ]
de Sanjose, Silvia [2 ]
机构
[1] Hosp Tortosa Verge de la Cinta, Dept Pathol, Tortosa 43500, Spain
[2] Hosp Llobregat, Catalan Inst Oncol, Barcelona, Spain
关键词
Lymphoproliferative disorders; Immune markers; Immunohistochemistry; Prognosis; Survival analysis; B-CELL LYMPHOMA; CYTOTOXIC T-LYMPHOCYTES; NON-HODGKIN-LYMPHOMA; HIGH NUMBERS; PROGNOSTIC-SIGNIFICANCE; TUMOR; EXPRESSION; CANCER; SURVIVAL; PATIENT;
D O I
10.1016/j.critrevonc.2008.09.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In lymphoproliferative syndromes, tumoural-immune cell interactions depend on a number of factors related to tumoural and immune cells. Recent gene expression data tend to confirm the decisive role of the reactive microenvironment in the development and clinical behaviour of lymphoproliferative syndromes, and encourage particular interest in the role of T cells and accessory cells. This systematic review brings together the accumulated knowledge about "immune signatures" in Hodgkin and non-Hodgkin lymphomas. Extracted results revealed that the presence of T lymphocytes, regulatory T cells and non-activated CTL in the reactive microenvironment appear commonly to be related with a favourable outcome in the majority of lymphoproliferative syndromes, whereas the presence of TAM, NK cells and activated CTLs appear more usually related with a poor prognosis. The direct involvement of these "immune signatures" in the histopathological morphology, classification, clinicobiological characteristics and outcome of affected patients stimulates the search for new and more appropriate immunotherapeutic strategies. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:103 / 113
页数:11
相关论文
共 59 条
[1]   Immune responses in cancer [J].
Adam, JK ;
Odhav, B ;
Bhoola, KD .
PHARMACOLOGY & THERAPEUTICS, 2003, 99 (01) :113-132
[2]   The role of interleukin-3 in classical Hodgkin's disease [J].
Aldinucci, D ;
Olivo, K ;
Lorenzon, D ;
Poletto, D ;
Gloghini, A ;
Carbone, A ;
Pinto, A .
LEUKEMIA & LYMPHOMA, 2005, 46 (03) :303-311
[3]   Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells [J].
Alvaro, T ;
Lejeune, M ;
Salvadó, MT ;
Bosch, R ;
García, JF ;
Jaén, J ;
Banham, AH ;
Roncador, G ;
Montalbán, C ;
Piris, MA .
CLINICAL CANCER RESEARCH, 2005, 11 (04) :1467-1473
[4]   Tumor-infiltrated immune response correlates with alterations in the apoptotic and cell cycle pathways in Hodgkin and Reed-Sternberg cells [J].
Alvaro, Tomas ;
Lejeune, Marylene ;
Garcia, Juan F. ;
Salvado, Ma. Teresa ;
Lopez, Carlos ;
Bosch, Ramon ;
Jaen, Joaquin ;
Escriva, Patricia ;
Pons, Lluis E. .
CLINICAL CANCER RESEARCH, 2008, 14 (03) :685-691
[5]   Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients [J].
Alvaro, Tomas ;
Lejeune, Marylene ;
Salvado, Maria-Teresa ;
Lopez, Carlos ;
Jaen, Joaquin ;
Bosch, Ramon ;
Pons, Lluis E. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5350-5357
[6]  
Alvaro T, 2006, HAEMATOLOGICA, V91, P1605
[7]   Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma:: A quantitative tissue microarray study in a large retrospective cohort of 267 patients [J].
Alvaro-Naranjo, T ;
Lejeune, M ;
Salvadó-Usach, MT ;
Bosch-Príncep, R ;
Reverter-Branchat, G ;
Jaén-Martínez, J ;
Pons-Ferré, LE .
LEUKEMIA & LYMPHOMA, 2005, 46 (11) :1581-1591
[8]   CD4+T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome [J].
Ansell, SM ;
Stenson, M ;
Habermann, TM ;
Jelinek, DF ;
Witzig, TE .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) :720-726
[9]   Mechanisms of lysis by cytotoxic T cells [J].
Atkinson, EA ;
Bleackley, RC .
CRITICAL REVIEWS IN IMMUNOLOGY, 1995, 15 (3-4) :359-384
[10]  
Azuma T, 2003, CANCER RES, V63, P4516